These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 38540775)

  • 21. Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.
    Aykul S; Huang L; Wang L; Das NM; Reisman S; Ray Y; Zhang Q; Rothman N; Nannuru KC; Kamat V; Brydges S; Troncone L; Johnsen L; Yu PB; Fazio S; Lees-Shepard J; Schutz K; Murphy AJ; Economides AN; Idone V; Hatsell SJ
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35511419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
    Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
    BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification.
    Wang H; Kaplan FS; Pignolo RJ
    Biomolecules; 2024 Jan; 14(2):. PubMed ID: 38397384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility.
    Lindborg CM; Al Mukaddam M; Baujat G; Cho TJ; De Cunto CL; Delai PLR; Eekhoff EMW; Haga N; Hsiao EC; Morhart R; de Ruiter R; Scott C; Seemann P; Szczepanek M; Tabarkiewicz J; Pignolo RJ; Kaplan FS
    Clin Orthop Relat Res; 2023 Dec; 481(12):2447-2458. PubMed ID: 37156007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy in Fibrodysplasia Ossificans Progressiva: A Case Report and Systematic Review of the Literature.
    Botman E; Netelenbos JC; Rustemeyer T; Schoonmade LJ; Nieuwenhuijzen JA; Teunissen BP; Visser M; Raijmakers P; Lammertsma AA; Dahele M; Eekhoff M
    Front Endocrinol (Lausanne); 2020; 11():6. PubMed ID: 32117050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.
    Pacifici M
    Bone; 2018 Apr; 109():267-275. PubMed ID: 28826842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes.
    Pignolo RJ; Baujat G; Brown MA; De Cunto C; Di Rocco M; Hsiao EC; Keen R; Al Mukaddam M; Sang KLQ; Wilson A; White B; Grogan DR; Kaplan FS
    Orphanet J Rare Dis; 2019 May; 14(1):98. PubMed ID: 31053156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
    Chakkalakal SA; Shore EM
    Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
    Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
    J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients.
    Wang H; De Cunto CL; Pignolo RJ; Kaplan FS
    Bone; 2021 Aug; 149():115978. PubMed ID: 33915334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clearance of Senescent Cells From Injured Muscle Abrogates Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
    Wang H; Zhang Q; Kaplan FS; Pignolo RJ
    J Bone Miner Res; 2022 Jan; 37(1):95-107. PubMed ID: 34633114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
    Ravazzolo R; Cappato S; Bocciardi R
    Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.
    Kaplan FS; Andolina JR; Adamson PC; Teachey DT; Finklestein JZ; Ebb DH; Whitehead B; Jacobs B; Siegel DM; Keen R; Hsiao E; Pignolo RJ
    Bone; 2018 Apr; 109():276-280. PubMed ID: 28736245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.
    Kaplan FS; Glaser DL; Pignolo RJ; Shore EM
    Expert Opin Biol Ther; 2007 May; 7(5):705-12. PubMed ID: 17477807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
    Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
    J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva.
    Rajapakse CS; Lindborg C; Wang H; Newman BT; Kobe EA; Chang G; Shore EM; Kaplan FS; Pignolo RJ
    Acad Radiol; 2017 Mar; 24(3):321-327. PubMed ID: 27989444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs.
    Maekawa H; Jin Y; Nishio M; Kawai S; Nagata S; Kamakura T; Yoshitomi H; Niwa A; Saito MK; Matsuda S; Toguchida J
    Orphanet J Rare Dis; 2022 Sep; 17(1):364. PubMed ID: 36131296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva.
    Wentworth KL; Bigay K; Chan TV; Ho JP; Morales BM; Connor J; Brooks E; Shahriar Salamat M; Sanchez HC; Wool G; Pignolo RJ; Kaplan FS; Hsiao EC
    Bone; 2018 Apr; 109():104-110. PubMed ID: 29033382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TGF-Beta Induces Activin A Production in Dermal Fibroblasts Derived from Patients with Fibrodysplasia Ossificans Progressiva.
    de Ruiter RD; Wisse LE; Schoenmaker T; Yaqub M; Sánchez-Duffhues G; Eekhoff EMW; Micha D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.
    Shore EM; Kaplan FS
    Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.